Australian Regulator Proposes Fee Increase To Offset Rising Costs
PwC Review Also Looking At New Costing Model
Executive Summary
A growing role in dealing with medicines shortages, COVID-19-related pressures and the costs of relocating to new premises are among the factors behind the TGA’s proposal to raise the fees it charges pharma firms for its regulatory services.